Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
10 2019
Historique:
received: 19 06 2019
revised: 24 07 2019
accepted: 29 07 2019
pubmed: 31 8 2019
medline: 8 9 2020
entrez: 31 8 2019
Statut: ppublish

Résumé

The appropriate use of antiemetics is important for the prevention of chemotherapy-induced nausea and vomiting (CINV); however, little is known about the rate of concordance with antiemetic guidelines for CINV in the field of pediatric, adolescent, and young adult. Using the Diagnosis Procedure Combination system in Japan, we identified patients <30 years of age who were diagnosed with cancer between July 2010 and March 2016. We have assessed concordance with the ASCO antiemetic guidelines for each emetic risk category of chemotherapeutic drugs. Furthermore, we have assessed the risk factors of discordance with the antiemetic guidelines using a logistic regression. In total, 21 106 patients who underwent chemotherapy were included. The rates of concordance with the guidelines in each emetic risk category of chemotherapeutic drugs were 51.1% in high risk, ≥18 years of age; 21.5% in high risk, <18 years of age; 32.1% in moderate risk; 52.0% in low risk; and 51.6% in minimal risk. The main reason for the discordance was underuse of antiemetics, especially steroids. The factors for discordance were younger age, use of moderate and high emetic risk chemotherapeutic drugs, hematological malignancy, and brain tumor. There is substantial scope to improve the antiemetic practice and reduce the risk of discordance with the antiemetic guidelines in pediatric, adolescent, and young adult patients. The risk factors are different from those in adults. Further investigations to evaluate the causes of discordance are warranted.

Identifiants

pubmed: 31469518
doi: 10.1002/cam4.2486
pmc: PMC6797697
doi:

Substances chimiques

Antiemetics 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6243-6249

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 16H02634
Pays : International
Organisme : Japan Society for the Promotion of Science
ID : 19H01075
Pays : International
Organisme : Health, Labor, and Welfare Policy Research
ID : H27-iryo-ippan-001
Pays : International
Organisme : Health, Labor, and Welfare Policy Research
ID : H30-seisaku-shitei-004
Pays : International

Informations de copyright

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

PLoS One. 2016 Nov 10;11(11):e0166269
pubmed: 27832182
Oncologist. 2015 Apr;20(4):450-8
pubmed: 25795636
Cancer Epidemiol. 2017 Dec;51:74-80
pubmed: 29078121
Br J Cancer. 2006 Apr 10;94(7):1011-5
pubmed: 16552437
J Clin Oncol. 2006 Jun 20;24(18):2932-47
pubmed: 16717289
Anticancer Res. 2012 Oct;32(10):4251-61
pubmed: 23060545
J Neurooncol. 1998 Mar;37(1):1-8
pubmed: 9525832
Int J Clin Oncol. 2016 Feb;21(1):1-12
pubmed: 26081252
Pediatr Blood Cancer. 2017 Oct;64(10):
pubmed: 28453189
Pediatr Blood Cancer. 2019 Jan;66(1):e27488
pubmed: 30318842
Cancer. 2002 Jul 1;95(1):155-63
pubmed: 12115329
Int J Clin Oncol. 2013 Dec;18(6):971-6
pubmed: 23011102
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
Pediatr Blood Cancer. 2019 May;66(5):e27646
pubmed: 30729654
Ann Med Health Sci Res. 2014 Nov;4(6):889-98
pubmed: 25506482
Support Care Cancer. 2017 Jan;25(1):323-331
pubmed: 27565788
Pediatr Blood Cancer. 2016 May;63(5):887-92
pubmed: 26864262
Strahlenther Onkol. 1999 Aug;175(8):392-6
pubmed: 10481771
Clin Infect Dis. 2012 Dec;55(12):1608-14
pubmed: 22955431
Neurology. 1997 Jun;48(6):1704-9
pubmed: 9191791
Drugs. 2013 Mar;73(3):249-62
pubmed: 23404093
Cancer Med. 2019 Oct;8(14):6243-6249
pubmed: 31469518
Support Care Cancer. 2012 Jan;20(1):141-7
pubmed: 21234609

Auteurs

Seiko Bun (S)

Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Pharmacy, National Center for Child Health and Development Hospital, Setagaya-ku, Japan.

Susumu Kunisawa (S)

Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Noriko Sasaki (N)

Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Kiyohide Fushimi (K)

Department of Health Policy and Informatics, Graduate School of Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Japan.

Kimikazu Matsumoto (K)

Department of Children's Oncology Center, National Center for Child health and Development Hospital, Setagaya-ku, Japan.

Akimasa Yamatani (A)

Department of Pharmacy, National Center for Child Health and Development Hospital, Setagaya-ku, Japan.

Yuichi Imanaka (Y)

Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH